Management of genetic epilepsies: From empirical treatment to precision medicine

Pharmacological Research

Volumn 107, Issue , 2016, Pages 426-429

  Striano, Pasquale ^a   Vari, Maria Stella ^a   Mazzocchetti, Chiara ^b   Verrotti, Alberto ^b   Zara, Federico ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

Antiepileptic drugs; Epilepsy; Management; Pharmacogenomics; Precision medicine; Review; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; ION CHANNEL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3;

DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG TRANSPORT; ENERGY METABOLISM; EPILEPSY; EPILEPTOGENESIS; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HIGH THROUGHPUT SEQUENCING; HUMAN; MOLECULAR DIAGNOSIS; MONOGENIC DISORDER; NEUROIMAGING; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SEIZURE; TREATMENT RESPONSE; GENETIC PREDISPOSITION; GENETICS;

ANTICONVULSANTS; EPILEPSY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PRECISION MEDICINE;

EID: 84963621739     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.04.006     Document Type: Article

References (49)

1. W. Hauser, J. Annegers, and L.T. Kurland Prevalence of epilepsy in Rochester, minnesota: 1940-1980 Epilepsia 32 1991 429 445
2. R.S. Fisher, C. Acevedo, A. Arzimanoglou, and et al. ILAE official report: a practical clinical definition of epilepsy Epilepsia 55 2014 475 482
3. P. Striano, and S. Striano New and investigational antiepileptic drugs Expert Opin. Invest. Drugs 18 2009 1875 1884
4. A.P. Aldenkamp, and G.A. Baker The Neurotoxicity Scale-II: results of a patient-based scale assessing neurotoxicity in patients with epilepsy Epilepsy Res. 27 1997 165 173
5. P. Striano, S. Striano, C. Minetti, and F. Zara Refractory, life-threatening status epilepticus in a 3-year-old girl Lancet Neurol. 7 2008 278 284
6. R.S. Møller RS, H.A. Dahl, and I. Helbig The contribution of next generation sequencing to epilepsy genetics Expert Rev. Mol. Diagn. 15 2015 1531 1538
7. C.T. Myers, and H.C. Mefford Advancing epilepsy genetics in the genomic era Genome Med. 7 2015 91
8. F. Nicita, P. De Liso, F.R. Danti, and et al. The genetics of monogenic idiopathic epilepsies and epileptic encephalopathies Seizure 21 2012 3 11
9. P. Striano, A. Coppola, R. Paravidino, and et al. Clinical significance of rare copy number variations in epilepsy: a case-control survey using microarray-based comparative genomic hybridization JAMA Neurol. 69 2012 322 330
10. A. Covanis Clinical management of epileptic encephalopathies of childhood and infancy Expert Rev. Neurother. 14 2014 687 701
11. P. Striano, P. de Jonghe, and F. Zara Genetic epileptic encephalopathies: is all written into the DNA? Epilepsia 54 suppl. (8) 2013 22 26
12. P. Striano Epilepsy Towards the Next Decade - New Trends and Hopes in Epileptology - Springer P. Striano, 2015 Springer Science-Business Media
13. P. Striano, and F. Zara Genetics: mutations in mTOR pathway linked to megalencephaly syndromes Nat. Rev. Neurol. 8 2012 542 544
14. A. Brunklaus, and S.M. Zuberi Dravet syndrome - from epileptic encephalopathy to channelopathy Epilepsia 55 2014 979 984
15. R. Sachdeo, A. Partiot, V. Biton, W.E. Rosenfeld, V. Nohria, D. Tompson, S. DeRossett, and R.J. Porter A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development Int. J. Clin. Pharmacol. Ther. 52 2014 509 518
16. S. Maljevic, and H. Lerche Potassium channel genes and benign familial neonatal epilepsy Prog. Brain Res. 213 2014 17 53
17. G. Orhan, M. Bock, D. Schepers, El. Ilina, S.N. Reichel, H. Löffler, N. Jezutkovic, S. Weckhuysen, S. Mandelstam, A. Suls, T. Danker, E. Guenther, I.E. Scheffer, P. de Jonghe, H. Lerche, and S. Maljevic Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy Ann. Neurol. 75 2014 382 394
18. S. Weckhuysen, V. Ivanovic, R. Hendrickx, and et al. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients Neurology 81 2013 1697 1703
19. A.L. Numis, M. Angriman, J.E. Sullivan, and et al. KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response Neurology 82 2014 368 370
20. J.R. Lemke, D. Lal, E.M. Reinthaler, and et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes Nat. Genet. 45 2013 1067 1072
21. T.M. Pierson, H. Yuan, E.D. Marsh, and et al. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine Ann. Clin. Transl. Neurol. 1 2014 190 198
22. R.S. Møller, S.E. Heron, L.H.G. Larsen, and et al. Mutations in KCNT1 cause a spectrum of focal epilepsies Epilepsia 56 2015 e114 120
23. C.J. Milligan, M. Li, E.V. Gazina, and et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine Ann. Neurol. 75 2014 581 590
24. M.A. Mikati, Y.H. Jiang, M. Carboni, and et al. Quinidine in the treatment of KCNT1-positive epilepsies Ann. Neurol. 78 6 2015 995 999
25. H. Yu, and V.W. Zhang Precision medicine for continuing phenotype expansion of human genetic diseases Biomed. Res. Int. 2015 745043
26. D. Kasperaviciute, and S.M. Sisodiya Epilepsy pharmacogenetics Pharmacogenomics 10 2009 817 836
27. S.M. Sisodiya, and C. Marini Genetics of antiepileptic drug resistance Curr. Opin. Neurol. 22 2009 150 156
28. W. Löscher Current status and future directions in the pharmacotherapy of epilepsy Trends Pharmacol. Sci. 23 2002 113 118
29. D. Schmidt, and W. Loscher Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms Epilepsia 46 2005 858 877
30. G.A. Anderson Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs Neurology 63 Suppl. (4) 2004 3 8
31. M.A. Lopez-Garcia, I.A. Feria-Romero, H. Fernando-Serrano, and et al. Genetic polymorphisms associated with antiepileptic metabolism Front. Biosci. (Elite Ed). 6 2014 377 386
32. V. Franco, and E. Perucca CYP2C9 polymorphism and phenytoin metabolism: implications for adverse effects Expert Opin. Drug Metabol. Toxicol. 11 2015 1269 1279
33. J. Saruwatari, T. Ishitsu, T. Seo, M. Shimomasuda, Y. Okada, S. Goto, R. Nagata, A. Takashima, S. Yoshida, N. Yasui-Furukori, S. Kaneko, and K. Nakagawa The clinical impact of cytochrome P450 polymorphisms on the anti-epileptic drug therapy Seizure 3 2010 34 50
34. K. Mamiya, A. Hadama, E. Yukawa, I. Ieiri, K. Otsubo, H. Ninomiya, N. Tashiro, and S. Higuchi CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics Eur. J. Clin. Pharmacol. 55 2000 821 825
35. T. Budi, K. Toth, A. Nagy, and et al. Clinical significance of CYP2C9-status guided valproic acid therapy in children Epilepsia 56 2015 849 855
36. X.M. Chu, L.F. Zhang, G.J. Wang, and et al. Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients Eur. J. Clin. Pharmacol. 68 2012 1395 1401
37. H. Potschka, and M.J. Brodie Pharmacoresistance Handb. Clin. Neurol. 108 2012 741 757
38. A. Siddiqui, R. Kerb, M.E. Weale, and et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1 N. Engl. J. Med. 348 2003 1442 1448
39. B.S. Haerian, K.S. Lim, C.T. Tan, and et al. Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis Pharmacogenomics 12 2011 713 725
40. F.G. Bournissen, M.E. Moretti, D.N. Juurlink, and et al. Polymorphism of the MDR1/ABCB1C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis Epilepsia 50 2009 898 903
41. S.K. Tate, C. Depondt, S.M. Sisodiya, and et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin Proc. Natl. Acad. Sci. U. S. A. 102 2005 5507 5512
42. N.C. Tan, S.E. Heron, I.E. Scheffer, and et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy Neurology 63 2004 1090 1092
43. I. Manna, A. Gambardella, A. Bianchi, P. Striano, R. Tozzi, U. Aguglia, F. Beccaria, P. Benna, R. Campostrini, M.P. Canevini, F. Condino, C. Durisotti, M. Elia, A.T. Giallonardo, A. Iudice, A. Abate, A. La Neve, R. Michelucci, G.C. Muscas, R. Paravidino, G. Zaccara, C. Zucca, F. Zara, and E. Perucca A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy Epilepsia 52 2011 e40 4
44. B.T. Zhou, Q.H. Zhou, J.Y. Yin, and et al. Effects of SCN1A and GABA-receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up CNS Neurosci. Ther. 18 2012 566 572
45. J. Qu, Y. Zhang, Z.Q. Yang, and et al. Gene-wide tagging study of the association between KCNT1 polymorphisms and the susceptibility and efficacy of genetic generalized epilepsy in Chinese population CNS Neurosci. Ther. 20 2014 140 146
46. P. Striano, and F. Zara Epilepsy: hLA alleles linked to carbamazepine hypersensitivity Nat. Rev. Neurol. 7 2011 365 366
47. W.H. Chung, S.I. Hung, J.Y. Yang, and et al. Granulysin is a key mediator for disseminated keratinocytes death in Steven-Johnson syndrome an toxic epidermal necrolysis Nat. Med. 14 2008 1343 1350
48. P.B. Ferrell Jr., and H.L. McLeod Carbamazepine, HLA-B∗1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: uS FDA recommendations Pharmacogenomics 9 2008 1543 1546
49. M. McCormack, A. Alfirevic, S. Bourgeois, and et al. HLA-A∗3101 and carbamazepine-induced hypersensitivity reactions in Europeans N. Engl. J. Med. 364 2011 1134 1143